SG11201803422RA - Compound for use in the prevention and treatment of neurodegenerative diseases - Google Patents

Compound for use in the prevention and treatment of neurodegenerative diseases

Info

Publication number
SG11201803422RA
SG11201803422RA SG11201803422RA SG11201803422RA SG11201803422RA SG 11201803422R A SG11201803422R A SG 11201803422RA SG 11201803422R A SG11201803422R A SG 11201803422RA SG 11201803422R A SG11201803422R A SG 11201803422RA SG 11201803422R A SG11201803422R A SG 11201803422RA
Authority
SG
Singapore
Prior art keywords
international
wien
compound
prevention
treatment
Prior art date
Application number
SG11201803422RA
Inventor
Robert; Konrat
Marco Sealey
Original Assignee
Univ Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16156775.5A external-priority patent/EP3207925A1/en
Application filed by Univ Wien filed Critical Univ Wien
Publication of SG11201803422RA publication Critical patent/SG11201803422RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 8 June 2017(08.06.2017) WIPOIPCT (10) International Publication Number WO 2017/093363 A1 (51) International Patent Classification: A61K 31/185 (2006.01) A61P 25/28 (2006.01) A61P 25/76(2006.01) (21) International Application Number: PCT/EP2016/079353 (22) International Filing Date: (25) Filing Language: (26) Publication Language 30 November 2016 (30.11.2016) English English (30) Priority Data: 15196984.7 30 November 2015 (30.11.2015) 16156775.5 22 February 2016 (22.02.2016) EP EP (71) Applicant: UNIVERSITAT WIEN [AT/AT]; Universitat- sring 1, 1010 Wien (AT). (72) Inventors: KONRAT, Robert; Favoritenstrasse 4-6, 1040 Wien (AT). SEALEY, Marco; Spengergasse 61/16, 1050 Wien (AT). (74) Agent: ISARPATENT - PATENT- UND RECHTSAN- WALTE BEHNISCH BARTH CHARLES HASSA PECKMANN UND PARTNER MBB; Friedrichstrafie 31, 80801 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) < ON n O (54) Title: COMPOUND FOR USE IN THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES (57) : The present invention is directed to a compound for use in the prevention or treatment of a neurodegenerative dis ease, in particular of a synucleinopathy. The present invention further is directed to a pharmaceutical composition containing an ef fective amount of said compound and one or more pharmaceutically acceptable auxiliaries.
SG11201803422RA 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases SG11201803422RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196984 2015-11-30
EP16156775.5A EP3207925A1 (en) 2016-02-22 2016-02-22 Compound for use in the prevention and treatment of neurodegenerative diseases
PCT/EP2016/079353 WO2017093363A1 (en) 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
SG11201803422RA true SG11201803422RA (en) 2018-06-28

Family

ID=57539219

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201803422RA SG11201803422RA (en) 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases
SG10202004908UA SG10202004908UA (en) 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202004908UA SG10202004908UA (en) 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases

Country Status (14)

Country Link
US (1) US11179358B2 (en)
EP (2) EP3735965A1 (en)
JP (2) JP7033073B2 (en)
CN (1) CN108601758A (en)
AU (1) AU2016364308B2 (en)
CA (1) CA3003841A1 (en)
DK (1) DK3383381T3 (en)
ES (1) ES2804541T3 (en)
HU (1) HUE050096T2 (en)
IL (1) IL259383B (en)
MX (1) MX2018006631A (en)
PT (1) PT3383381T (en)
SG (2) SG11201803422RA (en)
WO (1) WO2017093363A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020295671A1 (en) 2019-06-18 2022-01-20 Universität Wien Calixarene compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489612A (en) 1991-08-23 1996-02-06 The University Of Alabama At Birmingham Research Foundation Calixarene chloride-channel blockers
FR2782007B1 (en) 1998-08-05 2001-02-23 Centre Nat Rech Scient USE OF CALIX (N) ARENES FOR THE TREATMENT OF FIBROTIC DISEASES
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101052417A (en) * 2004-08-09 2007-10-10 艾兰制药公司 Prevention and treatment of synucleinopathic and amyloidogenic disease
FR2888937B1 (en) * 2005-07-21 2012-10-26 Biomerieux Sa METHOD OF DETECTING FCPA USING FCPA AGGREGATION AGENT AND FORM AGGREGATE CAPTURING AGENT
MY153198A (en) 2006-03-29 2015-01-29 Wista Lab Ltd Inhibitors of protein aggregation
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2017093363A1 (en) 2017-06-08
US11179358B2 (en) 2021-11-23
IL259383A (en) 2018-07-31
SG10202004908UA (en) 2020-06-29
CN108601758A (en) 2018-09-28
JP7033073B2 (en) 2022-03-09
AU2016364308B2 (en) 2022-03-10
EP3383381B1 (en) 2020-04-08
MX2018006631A (en) 2019-01-30
PT3383381T (en) 2020-07-03
EP3383381A1 (en) 2018-10-10
AU2016364308A1 (en) 2018-05-17
IL259383B (en) 2022-07-01
US20200360315A1 (en) 2020-11-19
DK3383381T3 (en) 2020-07-13
HUE050096T2 (en) 2020-11-30
JP2022027864A (en) 2022-02-14
JP2018535272A (en) 2018-11-29
EP3735965A1 (en) 2020-11-11
CA3003841A1 (en) 2017-06-08
ES2804541T3 (en) 2021-02-08

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201907034PA (en) Methods of treating influenza
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900501RA (en) Cannabis composition
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201808108XA (en) Synthesis of indazoles
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808686VA (en) Synthesis of indazoles
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900043TA (en) Antibody formulations
SG11201909906QA (en) Organic compounds
SG11201810123SA (en) Treatment of intrahepatic cholestatic diseases
SG11201805141QA (en) Compositions and methods for detecting and treating gastric cancer
SG11201907844TA (en) Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
SG11201809494VA (en) Pharmaceutical composition comprising eteplirsen